• Explore /
  • Poster
  • / Health-related quality of life (HRQOL) with pembrolizumab (pembro) plus trastuzumab (tras) and chemotherapy (chemo) in first-line HER2-positive (HER2+) advanced gastric cancer: KEYNOTE-811 trial results.

Health-related quality of life (HRQOL) with pembrolizumab (pembro) plus trastuzumab (tras) and chemotherapy (chemo) in first-line HER2-positive (HER2+) advanced gastric cancer: KEYNOTE-811 trial results.

Abstract Poster

Authors

Yelena Janjigian

Yelena Y. Janjigian

Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY

Yelena Y. Janjigian , Akihito Kawazoe , Jianming Xu , Sara Lonardi , Jean-Philippe Metges , Lucjan S. Wyrwicz , Lin Shen , Yuriy Ostapenko , Mehmet Bilici , Maeve Aine Lowery , Adriana Valderrama , Yanfen Guan , Kan Li , Chie-Schin Shih , Sun Young Rha

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Patient-Reported Outcomes and Real-World Evidence

Clinical Trial Registration Number

NCT03615326

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr 286)

DOI

10.1200/JCO.2024.42.3_suppl.286

Abstract #

286

Poster Bd #

D6

Abstract Disclosures

Similar Posters

First Author: Zev A. Wainberg

First Author: Lin Shen

First Author: Sun Young Rha

First Author: Ryan Sugarman